Experts compared 108,215 survivors of one of the 20 most common cancers from the UK Clinical Practice Research Datalink with 523,541 controls. It was found that in survivors of 18 out of 20 types of cancer of certain localizations, the risk of developing venous thromboembolism increased by 2–10 times compared with participants in the opposite group. Similarly, survivors of 10 of 20 single-site cancers (including hematologic, kidney, lung, and ovarian cancers) were at increased risk for heart failure (HF) or cardiomyopathy. Multiple cancers, including hematologic malignancies, increased the risk of arrhythmia, pericarditis, coronary artery disease, stroke, and valvular heart disease.
In addition, the relative risk for HF or cardiomyopathy and venous thromboembolism was higher in group 1 participants without a history of CVD and in younger patients. Also, according to experts, the increased risk of these outcomes was most pronounced in patients receiving chemotherapy.
The authors of the study emphasized that the results obtained indicate the need for preventive measures and earlier intervention to prevent the development of CVD in patients who have had cancer of certain localizations.